Ophthalmology Times Europe E-News:
Having trouble viewing this e-mail? Click here. 		You are subscribed to Ophthalmology Times Europe.
Ophthalmology Times Europe E-News
Modern Medicine Network
 
 
 
 
In this issue
• Ketorolac and ranibizumab combo
• Ocriplasmin offers “major added value”
• Good binocular results in exotropia
• CXL could prevent keratoconus progression
 
 
Survey

Would you use a dexamethasone implant and bevacizumab combo for CRVO?

Yes
86%
No
14%

You can now follow us on Twitter:
www.twitter.com/oteurope

Contact Us
Click here to contact Felicity Thomas, editor.
August 14, 2013
Ketorolac eyedrops and ranibizumab combo reduces CMT
A combination of ketorolac eyedrops 0.45% and intravitreal ranibizumab reduces central macular thickness (CMT) in choroidal neovascularisation (CNV), reveals a recent paper.
More...
Ocriplasmin "major added value" for VMT treatment
Jetrea, developed by ThromboGenics, offers “major added value” for the treatment of vitreomacula traction and macular hole, claims the German Institute for Quality and Efficiency in Health Care (IQWiG). More...
Good binocular results in children with early-onset exotropia
The surgical outcomes for children treated for constant early-onset exotropia demonstrated good binocular results, claims a study in the journal Eye. More...
CXL could treat stages of keratoconus
Corneal collagen crosslinking (CXL) could successfully treat certain stages of keratoconus, according to a recent published paper. More...